Latest research on Symlin

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

Latest findings

For diabetes, we found that the reviews for seven drugs (Apidra, Symlin, Exubera, Januvia, Janumet, Victoza and Bydureon) discussed the rationale for use of surrogates and three of them (Symlin, Victoza and Bydureon) justified choosing glycaemic control as an outcome by clearly stating the evidence that corresponds to the highest level of evidence for surrogacy using the ICH-9 criteria. [source, 2015]
We found that a review for one drug in COPD (Arcapta Neohaler) mentioned a MID and reviews for 12 drugs in diabetes (Avandaryl, Symlin, Duetact, Exubera, Januvia, BYETTA, Cycloset, Onglyza, Kombiglyze XR, Victoza, Tradjenta and Bydureon) mentioned a threshold (number of patients achieving the target haemoglobin A1C level) that is linked to patient-centred outcomes. [source, 2015]
This amylin derivative was initially called Symlin and thereafter marketed as pramlintide and is used as an adjunct to insulin in the management of type II diabetes [126–139]. [source, 2013]
Other drugs include recently approved Symlin (Pramlintide Acetate), as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy, and Levemir (Insulin detemir) which is indicated for once or twice daily subcutaneous administration in the treatment of adult patients with Type 1 DM who require basal (long-acting) insulin for the control of hyperglycemia. [source, 2013]
Pramlintide (Symlin), a synthetic, soluble analog of human amylin, was approved by the FDA in 2005 as an antihyperglycemic agent for patients with diabetes as adjunctive therapy to mealtime insulin. [source, 2012]
Pramlintide (Symlin) is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insulin in response to nutrient stimuli. [source, 2011]
Pramlintide (Symlin) is available as an injectable adjunct to insulin therapy. [source, 2010]
Drug accumulation is not anticipated in hepatic dysfunction (Symlin). [source, 2009]
Despite these results, the pramlintide manufacturer recommends not mixing insulin and pramlintide in the same syringe (Symlin). [source, 2009]
No other drug interactions have been reported (Symlin). [source, 2009]